Tobias Arkenau (@EllipsesCMO) profile picture
England, United Kingdom
Joined May 2012
Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)
AS SEEN ON TV: Learn about our role in advancing Precision Medicine and how we validate promising assets through our Scientific Advisory Group. Check out the interview: ellipses.life/ellipses-pharm… #PrecisionMedicine #EllipsesPharma
2
2
84
EP0031, our next-gen RET inhibitor, receives FDA Orphan Drug Designation. A crucial step in advancing cancer treatments. #OrphanDrug #EP0031 #EllipsesPharma ellipses.life/ellipses-ep003…
3
3
85
📄 Access the poster presentation for Asset EP0031, shared by @EllipsesCMO at @AACR Boston. Dive into the details and join us in advancing cancer research!💡ellipses.life/wp-content/upl… #AACR2023 #CancerInnovation 🚀
2
85
#Targets23 Great work from Drs. @AriMarinel @mihaela_aldea and others on characterizing outcomes in #RET NSCLC post progression on selective inhibitors: patterns of progression, response to subsequent lines of therapy. – at Huntington Avenue - Prudential Center, Boston
2
5
1
39
5,209
I was happy to see Dr. @ElenaGarralda again - presenting work on EP0031, a next generation #RET inhibitor with impressive efficacy after selective RET inhibitors and CNS efficacy. #Targets23
1
8
30
2,826
🎯 🧬 KL590586 (A400/EP0031) A next-generation selective RET inhibitor in patients with RET-altered solid tumors. ORR 60% and DCR 95% for all tumor types and doses. 🫁 In NSCLC: ORR 81% in 1L and 70% in 2L. Also 🧠 activity proven #ASCO23 #LCSM
1
14
25
3,310
Tobias Arkenau retweeted
The burden of bureaucracy in clinical research has increased for investigators & clinical research teams. ESMO proposes a framework to streamline clinical research & reduce the bureaucracy in clinical trials, promoting better care for cancer patients. 🔗annalsofoncology.org/article…
1/ Bureaucracy is overwhelming Clinical Research! ESMO proposes principles to improve Sponsoring and Monitoring of Clinical Trials and promote patient welfare Follow thread for examples & proposals, share if you agree! #StreamlineClinicalResearch @myESMO bit.ly/3XZ63WY
4
32
9
62
35,479
We are excited to share our latest cancer research insights through more than 140 abstracts and presentations at #ASCO22. Read about where you can find our scientific experts at this year’s annual meeting. sarahcannon.com/about/newsro…
3
9
Excited to be on our first call for the new ⁦@ASCO⁩ monthly plenary series. See attached for dates of presentations and submissions. Exciting to get data out there within 5-6 weeks of submission. Monthly Plenary Series | ASCO asco.org/meetings-education/…
6
22
Tobias Arkenau retweeted
Be the first to hear the latest HemOnc news and best practice from the world’s leading experts 👨‍🔬👩‍🔬 Stay tuned for videos, podcasts and articles published live from the latest virtual meetings! #HemOnc #Leusm #Lymsm #MMSM #MDSsm #MPNsm #BMTsm #CTSM #ImmunoOnc #BleedingDisorders
8
31
1
219
Happy Fourth of July! Wishing you a safe and enjoyable holiday with friends and family. #July4th
Tobias Arkenau retweeted
🕙 Just 10 days to go until ESMO #WorldGI2021 starts and @VJOncology are excited to report on the biggest news from the meeting Check out 👉 vjoncology.com 👈 for exclusive interviews, podcasts and more! @myESMO #CRCSM #HPBCsm #STCsm #ESOCsm #GICancer #ayacsm
2
2
Tobias Arkenau retweeted
Enjoying the gastrointestinal cancer oral abstract session? 🤔 Register to our upcoming #VJSession, a roundtable discussion on the latest learnings in GI from #ASCO21 Register here ➡️tinyurl.com/the-gi-session @ASCO @OncoAlert #GIsm
1
3
Tobias Arkenau retweeted
Register now for @VJOncology's post-ASCO VJSessions! Join us for a series of roundtable discussions with #oncology experts to review key highlights from #ASCO21 Click for more details 👇👇 GI: tinyurl.com/GI-session GU: tinyurl.com/gu-sessions Breast: tinyurl.com/breast-sessions
Tobias Arkenau retweeted
#MCCRWorkshop The Workshop is organised by @EORTC @myESMO and @AACR and has provided training to over 1800 investigators from all over the world since its’ inception in 1999. Apply NOW eortc.org/mccr #clinicaltrialdesign #clinicaltrials
Tobias Arkenau retweeted
Outstanding program this weekend! @BandVsCancer
This afternoon, we kick off Sarah Cannon’s 24th Annual Scientific Meeting by taking a look back at scientific advancements with the ‘Year In Review’ session lead by @deehubie @BurrisSkip and @dave6408
2
8
Did you know that Sarah Cannon enrolls more than 3,000 patients per year on clinical trials? We are so grateful to these patients who are helping to advance science & transform care for people facing cancer. Learn more at SarahCannon.com. #NationalHealthQualityWeek
2
5
Tobias Arkenau retweeted
Debating rectal cancer management #EIOC2020 @geriradonc @Shaheenah1 @agrothey @SirohiBhawna #globalpanel @MedDirSCRI – at Lebanon
1
3
15